The Phase 3 trial evaluating Aficamten for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) completed primary data collection on 2025-02-28. This study compared Aficamten to metoprolol succinate in adult patients.
Background
Obstructive hypertrophic cardiomyopathy (oHCM) is a heart condition involving thickening of the heart muscle and left ventricular outflow tract obstruction.
Trial design
This completed trial (NCT05767346) is a Phase 3 study that enrolled 175 participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The study's purpose was to compare the efficacy and safety of aficamten (CK-3773274) against metoprolol succinate in adults with this condition. Intervention arms included aficamten (at doses of 5 mg, 10 mg, 15 mg, and 20 mg) and metoprolol succinate (at doses of 50 mg, 100 mg, 150 mg, and 200 mg), along with their respective placebos.
What this means
The primary completion of this Phase 3 trial indicates that all planned data collection for the study has concluded. The next step will involve data analysis to determine the efficacy and safety profile of aficamten compared to metoprolol succinate for patients with symptomatic oHCM. Results from this study will be important for understanding the potential role of aficamten in treating this condition.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05767346, titled "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM," was updated with a primary completion date of 2025-02-28 on clinicaltrials.gov.